EmeraMed Overview
- Founded
-
2007
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
Angel
- Latest Deal Amount
-
$274K
EmeraMed General Information
Description
Operator of a biotechnology firm intended to develop the lipophilic blood-brain-barrier passing antioxidant emeramide. The company focuses on chelating free iron as well as many heavy metals, such as mercury and lead, which would otherwise create free radicals, enabling healthcare providers to restore normal function to the mitochondria and improve overall health.
Contact Information
Website
www.emeramed.com
Formerly Known As
Ermes Medical Co
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- Trinity House, Charleston Road
- Ranelagh
- Dublin 6
- Ireland
+353 (092) 000 000
EmeraMed Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Angel (individual) | 15-Nov-2016 | $274K | 00.000 | Completed | Clinical Trials - Phase 2 | |
| 1. Seed Round | 17-Jun-2016 | 00.000 | 00.000 | Completed | Clinical Trials - Phase 2 |
EmeraMed Patents
EmeraMed Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202213577-D0 | New pharmaceutical use | Pending | 15-Sep-2022 | ||
| GB-202212071-D0 | New medical uses | Pending | 18-Aug-2022 | ||
| GB-202113078-D0 | New pharmaceutical use | Inactive | 14-Sep-2021 | ||
| GB-202111911-D0 | New medical uses | Inactive | 19-Aug-2021 | ||
| GB-202014420-D0 | New pharmaceutical use | Inactive | 14-Sep-2020 |
EmeraMed Executive Team (3)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Boyd Haley Ph.D | Founder, Chief Executive Officer, Chief Scientist & Board Member | ||
| Ragnar Klingberg | Executive Officer & Board Member |
EmeraMed Board Members (5)
| Name | Representing | Role | Since |
|---|---|---|---|
| Boyd Haley Ph.D | EmeraMed | Founder, Chief Executive Officer, Chief Scientist & Board Member | 000 0000 |
| David Kennedy | Self | Board Member | 000 0000 |
| Kathryn Wachsman JD | EmeraMed | Board Member | 000 0000 |
| Paul Reicherter MD | EmeraMed | Board Member | 000 0000 |
| Ragnar Klingberg | EmeraMed | Executive Officer & Board Member | 000 0000 |
EmeraMed Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
EmeraMed Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000 0000000 | 01-Jul-2014 | 0000000000 | Biotechnology | 0000 0000 |